Drug Development

Clinical Trials Regulatory Approval Market Competition Market Launches Oncology Pharmaceutical Research Clinical Research Market Trends Research and Development Regulatory Affairs Weight-loss Drugs FDA Approval Weight Loss Drugs Alzheimer's Treatment Cancer Treatments Biosimilars GLP-1 Medications FDA Regulations Drug Screening Cost Analysis Medicinal Formulations Sofpironium Bromide Market Dynamics Molecular Biology Market Share Biologics Innovative Treatments Pediatric Medication Clinical Trends Clinical Studies Immune Response Combination Therapies Biotechnology Preventive Medicine Innovative Therapies Generic Pharmaceuticals Weight Management Regulatory Issues Chemical Entities Phase III Trials Collaboration in Pharma Vaccine Development Innovation Pipeline Non-invasive Techniques Market Potential Personalized Medicine Biopharmaceuticals AI Applications Generic Drugs Pipeline Metabolic Disorders Cellular Biology Immunology Experimental Treatments Pipeline Management Regulatory Review Market Entry Strategies Pipeline Expansion HIV Prevention Immuno-Oncology Side Effects AI in Drug Discovery Respiratory Diseases Cell Therapy Antidepressants Clinical Therapies Regulatory Agencies Cancer Therapies FDA Approval Process GLP-1 Candidates Regulatory Approvals Pipeline Strategies Acquisition Strategies Phase 3 Trials FDA Approvals New Products Psychedelic Research Oral Medications AI in Healthcare Gene Therapy Larger-Molecule Drugs Injectable Drugs Obesity Drugs Phase 3 Clinical Trials Antiviral Drugs Obesity Treatments

Lilly to Acquire AtaiBeckley in Deal Valued Up to $3.8 Billion

The purchase puts a Breakthrough‑designated intranasal 5‑MeO‑DMT into Lilly's neuroscience portfolio, potentially speeding its development.

Zymeworks to Buy Theravance for $929 Million

Lilly Wins Exclusive License to Ascidian RNA Exon-Editing Platform for Kidney Diseases

HCW Biologics Prices Roughly $4 Million At‑The‑Market Private Placement

HCW Biologics Posts Surprise Q1 Profit on Trimmune Deal as Listing Risk Lingers

Cellular Intelligence Takes Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy

SIGA Expects $13 Million TPOXX Delivery in Q2 After Quiet Start to 2026

Regeneron and Telix Form 50/50 Partnership to Develop Targeted Radiopharmaceuticals

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Barclays Starts Merck at Overweight on 2026 Pipeline Catalysts as WSJ Reports Business Split Plan

FDA Approves Vanda’s Bysanti for Bipolar I Mania and Schizophrenia

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Takeda Strikes Multi-Year AI Drug Discovery Pact With Iambic Worth Over $1.7 Billion

Novo Nordisk’s Oral Wegovy Debuts With Strong Prescriptions as BMO Stays Cautious

Lilly Signs Up to $1.12 Billion Gene-Editing Pact to Tackle Hearing Loss

Insilico Medicine Surges on Hong Kong Debut After HK$2.3 Billion IPO

Prolynx Raises $70 Million to Advance Ultra-Long-Acting Obesity Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Praxis Relutrigine Study Halted Early for Efficacy as FDA Review Meeting Set